Cargando…
Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches
PURPOSE: The aim of this study was to investigate the performance and the reversibility of different classes of Hyaluronic Acid (HA) dermal fillers. We analysed 4 HA based fillers, belonging to 3 different chemical classes of products, commonly used in the field of wrinkles correction: linear HA 8 m...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744867/ https://www.ncbi.nlm.nih.gov/pubmed/36523543 http://dx.doi.org/10.2147/CCID.S383354 |
_version_ | 1784849020867313664 |
---|---|
author | Scrima, Mario Merola, Filomena Vito, Nicoletta Pacchioni, Daniele Vecchi, Gabriele Melito, Carmela Iorio, Antonio Giori, Andrea Maria Ferravante, Angela |
author_facet | Scrima, Mario Merola, Filomena Vito, Nicoletta Pacchioni, Daniele Vecchi, Gabriele Melito, Carmela Iorio, Antonio Giori, Andrea Maria Ferravante, Angela |
author_sort | Scrima, Mario |
collection | PubMed |
description | PURPOSE: The aim of this study was to investigate the performance and the reversibility of different classes of Hyaluronic Acid (HA) dermal fillers. We analysed 4 HA based fillers, belonging to 3 different chemical classes of products, commonly used in the field of wrinkles correction: linear HA 8 mg/mL (Viscoderm 0.8), thermically stabilized hybrid complexes of high and low molecular weight HA molecules at a concentration of 32 mg/mL and 45 mg/mL respectively (Profhilo and Profhilo Structura) and cross-linked HA 25 mg/mL (Aliaxin GP). METHODS: The products were tested by a well-established animal model. The generated implants were analyzed through High-Frequency Ultrasound technology. Then, reversibility of the treatment was evaluated by enzymatic degradation kinetics studies, characterised by a combined approach of Carbazole assay and HP-SEC/TDA method. RESULTS: Implants generated by linear HA 8 mg/mL remained detectable by ultrasound acquisition for 4 weeks, whereas those generated by injection of HA hybrid complex 32 mg/mL were detectable for 10 weeks. HA hybrid complex 45 mg/mL and cross-linked HA 25 mg/mL were detectable for 29 and at least 33 weeks, respectively. Enzymatic degradation kinetics studies demonstrated that the HA content in HA hybrid complex 45 mg/mL was almost completely depolymerized and homogeneous after 3 h of treatment. For cross-linked HA 25 mg/mL, 24 h of incubation are needed to obtain the same degree of depolymerization. CONCLUSION: The study confirmed the ability of the experimental model to predict the behaviour of HA based dermal fillers in vivo and showed the innovative aspects of HA hybrid complex 45 mg/mL, that combines the high-safety profile, in terms of reversibility of the treatment, of the linear HA-based products with the durability of a high degree cross-linked gels, paving the way to the chance to be used for a wide range of applications in the field of aesthetic medicine. |
format | Online Article Text |
id | pubmed-9744867 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-97448672022-12-14 Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches Scrima, Mario Merola, Filomena Vito, Nicoletta Pacchioni, Daniele Vecchi, Gabriele Melito, Carmela Iorio, Antonio Giori, Andrea Maria Ferravante, Angela Clin Cosmet Investig Dermatol Original Research PURPOSE: The aim of this study was to investigate the performance and the reversibility of different classes of Hyaluronic Acid (HA) dermal fillers. We analysed 4 HA based fillers, belonging to 3 different chemical classes of products, commonly used in the field of wrinkles correction: linear HA 8 mg/mL (Viscoderm 0.8), thermically stabilized hybrid complexes of high and low molecular weight HA molecules at a concentration of 32 mg/mL and 45 mg/mL respectively (Profhilo and Profhilo Structura) and cross-linked HA 25 mg/mL (Aliaxin GP). METHODS: The products were tested by a well-established animal model. The generated implants were analyzed through High-Frequency Ultrasound technology. Then, reversibility of the treatment was evaluated by enzymatic degradation kinetics studies, characterised by a combined approach of Carbazole assay and HP-SEC/TDA method. RESULTS: Implants generated by linear HA 8 mg/mL remained detectable by ultrasound acquisition for 4 weeks, whereas those generated by injection of HA hybrid complex 32 mg/mL were detectable for 10 weeks. HA hybrid complex 45 mg/mL and cross-linked HA 25 mg/mL were detectable for 29 and at least 33 weeks, respectively. Enzymatic degradation kinetics studies demonstrated that the HA content in HA hybrid complex 45 mg/mL was almost completely depolymerized and homogeneous after 3 h of treatment. For cross-linked HA 25 mg/mL, 24 h of incubation are needed to obtain the same degree of depolymerization. CONCLUSION: The study confirmed the ability of the experimental model to predict the behaviour of HA based dermal fillers in vivo and showed the innovative aspects of HA hybrid complex 45 mg/mL, that combines the high-safety profile, in terms of reversibility of the treatment, of the linear HA-based products with the durability of a high degree cross-linked gels, paving the way to the chance to be used for a wide range of applications in the field of aesthetic medicine. Dove 2022-12-08 /pmc/articles/PMC9744867/ /pubmed/36523543 http://dx.doi.org/10.2147/CCID.S383354 Text en © 2022 Scrima et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Scrima, Mario Merola, Filomena Vito, Nicoletta Pacchioni, Daniele Vecchi, Gabriele Melito, Carmela Iorio, Antonio Giori, Andrea Maria Ferravante, Angela Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches |
title | Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches |
title_full | Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches |
title_fullStr | Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches |
title_full_unstemmed | Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches |
title_short | Elucidations on the Performance and Reversibility of Treatment with Hyaluronic Acid Based Dermal Fillers: In vivo and in vitro Approaches |
title_sort | elucidations on the performance and reversibility of treatment with hyaluronic acid based dermal fillers: in vivo and in vitro approaches |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744867/ https://www.ncbi.nlm.nih.gov/pubmed/36523543 http://dx.doi.org/10.2147/CCID.S383354 |
work_keys_str_mv | AT scrimamario elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches AT merolafilomena elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches AT vitonicoletta elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches AT pacchionidaniele elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches AT vecchigabriele elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches AT melitocarmela elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches AT iorioantonio elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches AT gioriandreamaria elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches AT ferravanteangela elucidationsontheperformanceandreversibilityoftreatmentwithhyaluronicacidbaseddermalfillersinvivoandinvitroapproaches |